Valuation dashboard for Genprex, Inc. (GNPX) with P/E N/A, P/B 0.10, EV/EBITDA 0.85 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.41, GNPX has negative trailing earnings (P/E not meaningful) and an ROE of -163.13%. Market capitalisation stands at $2M.
Balance sheet quality for GNPX: current ratio of 3.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.10 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $168.13 |
| vs Current Price | +4830.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GNPX | Genprex, Inc. | $2M | 0.10 | -163.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.41 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -163.13% |
| Return on Invested Capital | -107.08% |
| Return on Assets | -96.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BDRX · BIVI · CERO · CMMB · CNSP · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of GNPX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks